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One thousand people die of asthma every day1; two thousand children die of 
pneumonia;2 lung cancer is the commonest cause of cancer deaths(#); and chronic 
obstructive pulmonary disease is predicted to be the fourth greatest cause of early 
death by 2040.3 Respiratory diseases generate an enormous burden of mortality, the 
majority of  falls on people in the global south and vulnerable populations in high 
income economies.4 They are diseases of poverty and disadvantage which further 
compound inequity by increased disability, loss of productivity and catastrophic out-
of-pocket health costs (**). As a major driver of ill-health and poverty, the burden of 
respiratory disease  is a global rate-limiting step towards achieving health equity, 




Research is also needed to address the unwarranted variation in access to and 
quality of respiratory diagnosis and care in LMICs.Error! Bookmark not defined. 
Underuse of effective interventions and overuse of ineffective or expensive 
interventions are important problems. For example  the overuse of bronchodilators 
and underuse of inhaled corticosteroids in asthma, underuse of nicotine replacement 
therapy in treating tobacco dependence and poor adherence to TB treatment.8 
 
Yet if we look at the World Health Organization’s (WHO’s) latest analysis of research 
expenditure from 12 major funders, from 2012-2017,9 where is respiratory disease? 
Almost three-quarters of grants were for non-communicable diseases (NCD), but 
respiratory disease lies 13th in the NCD category list with 2% of total; and by disease, 
TB lies 19th, asthma 27th; COPD 50th.  Only 0.2% of research funding went to low 
income countries.   Of the 450 grants received by African countries, allocations to  
respiratory diseases were: TB n=39; lower respiratory infections n= 7 grants; and 
asthma n= 2 grants.  The situation in other regions is worse: only 19 grants to south-



















There is a substantial mismatch between burden and 
research investment. This has not improved in over a 
decade.10 11 Although necessarily limited by data availability, 
our analysis suggests that advocacy for respiratory research 
has not been successful in communicating the urgency or size 
of the problem. There is no research strategy or feasible 
roadmap that aligns the interests of all stakeholders: 
governmental and commercial research funders, academic 
institutions, global and national health agencies, clinicians, 
patients and the public.  Therefore there is a need for national 
recognition and investment, plus a rebalancing of global 
investment in LMICs that have the biggest burden but least 
resource. Furthermore, the contribution of tobacco 
dependence, air pollution, and nutrition to respiratory 
morbidity means that to have impact, respiratory health research needs to 
increasingly expand its focus and partnerships beyond the health sector and health 
systems. 
 
Comment: We have a number of options for the infographic  to show size of respiratory 
research funding compared to respiratory burden – potentially compared to CVD (but mayt be 
same problem in LMICS for CVD too). Eg  Would a river plot based on proportions of 
funding/burden work? Or take a proxy for one condition eg COPD. We welcome your advice 
It has mapped disease burden and research opportunities, and is beginning to 
prioritise the most important questions to present to research funders.  
 
There is an urgent need for the respiratory research community work more effectively 
with other stakeholders to increase recognition of the catastrophic burden of 
respiratory diseases and to develop, test, implement and scale-up the necessary 
multiple and multi-sectoral strategies to turn the tide of respiratory ill-health.  In 
addition to improving national recognition of the problems, as China has illustrated,13 
donors have a key role to ensure that research funding reflects the burden and 
recognises the substantial opportunities to increase impact. In its first Global Health 
Research call, the NIHR committed 12% of the total allocation to responsive 
respiratory research in DAC listed countries.  This has triggered the formation of a 
global health respiratory network (GHRN)14: a meta-collaboration of  UK respiratory 
research institutions and their global health partners. The GHRN has created 
opportunities for synergistic working between research programmes in areas ranging 
from risk factors such as microbial resistance and exposure to air pollution to health 
systems strengthening  across the spectrum of communicable and non 
communicable respiratory diseases. We call on all funders to publish and review their 
research spend on respiratory health. We ask them to work synergistically to build on 
early investment and to share a roadmap15 that minimises the risk of duplication and 
helps maximise the impact on health, wellbeing and economic growth.  
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